Prism Medico & Pharmacy Ltd
Incorporated in 1985, Prism Medico & Pharmacy Ltd manufactures, trades, and distributes chemicals, medicines, pharmaceuticals, cosmetics, and related products[1]
- Market Cap ₹ 11.3 Cr.
- Current Price ₹ 18.6
- High / Low ₹ 24.8 / 11.6
- Stock P/E
- Book Value ₹ 21.7
- Dividend Yield 0.00 %
- ROCE 1.65 %
- ROE 1.09 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.86 times its book value
- Debtor days have improved from 35.1 to 21.0 days.
- Company's working capital requirements have reduced from 94.1 days to 14.5 days
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 25.0%
- Company has a low return on equity of -0.26% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | TTM | |
|---|---|---|---|---|
| 5.27 | 22.78 | 54.43 | 41.89 | |
| Interest | 0.14 | 0.29 | 0.11 | 0.18 |
| 5.21 | 21.95 | 54.10 | 42.07 | |
| Financing Profit | -0.08 | 0.54 | 0.22 | -0.36 |
| Financing Margin % | -1.52% | 2.37% | 0.40% | -0.86% |
| 0.07 | -0.03 | 0.07 | 0.08 | |
| Depreciation | 0.21 | 0.45 | 0.38 | 0.33 |
| Profit before tax | -0.22 | 0.06 | -0.09 | -0.61 |
| Tax % | 4.55% | 116.67% | -144.44% | |
| -0.22 | -0.00 | 0.04 | -0.55 | |
| EPS in Rs | -0.36 | -0.00 | 0.07 | -0.91 |
| Dividend Payout % | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -245% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -10% |
| 3 Years: | -21% |
| 1 Year: | 8% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 0% |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Sep 2019 | |
|---|---|---|---|---|
| Equity Capital | 6.06 | 6.06 | 6.06 | 6.06 |
| Reserves | 6.81 | 6.81 | 6.85 | 7.10 |
| Borrowing | 3.50 | 2.18 | 2.27 | -0.00 |
| 0.89 | 0.75 | 6.03 | 11.73 | |
| Total Liabilities | 17.26 | 15.80 | 21.21 | 24.89 |
| 9.91 | 9.31 | 8.91 | 8.94 | |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | 2.61 | 1.36 | 1.36 |
| 7.35 | 3.88 | 10.94 | 14.59 | |
| Total Assets | 17.26 | 15.80 | 21.21 | 24.89 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|
| -0.00 | 3.55 | -0.44 | |
| -0.00 | -2.53 | -0.00 | |
| -0.00 | -1.61 | -0.50 | |
| Net Cash Flow | -0.00 | -0.59 | -0.95 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|
| ROE % | -1.71% | -0.16% | 1.09% |
Documents
Announcements
-
Board Meeting Intimation for Consideration, Approval And Taking On Record The Unaudited Standalone Financial Results Of The Company Along With The Limited Review Report For The Quarter Ended 31St December, 2025.
2d - Board meeting on 13 Feb 2026 to consider unaudited quarter ended 31 Dec 2025 results.
-
Undertaking Of Functional Website
30 Jan - Website updated and functional (https://www.prismmedico.in), notified 28 Jan 2026.
-
Investor Complaints As Per Regulation 13(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
16 Jan - Quarterly investor complaints report for period ended 31/12/2025: zero complaints received, pending, or unresolved.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Jan - Confirmation certificate under Reg 74(5) for quarter ended 31-Dec-2025; no dematerialisations.
-
Compliance-57 (5) : intimation after the end of quarter
2 Jan - Company confirms no NCS issued and no payments due Oct 1–Dec 31, 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
PMPL deals in chemicals, serums, chemical products, antibiotics, medicines, drugs,
pharmaceuticals, pesticides, dyes, soaps, oils, perfumes, cosmetics, patent medicines, etc.